TGA
Lucentis now TGA-approved for retinopathy of prematurity
The Therapeutic Goods Administration (TGA) has granted Lucentis (ranibizumab) an indication for retinopathy of prematurity (ROP), making it the first...
Read more
Glaukos announces TGA approval of late-stage glaucoma implant
Glaukos has secured Australian regulatory approval for the Preserflo MicroShunt, offering late-stage glaucoma patients a more elegant surgical alternative to...
Read more
TGA approves Luxturna gene therapy
In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true...
Read more